Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Side effects
Page 19 of 21 of this archive, newest first.
What STEP 4 and SURMOUNT-4 actually established
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
South Africa pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Reflux, early satiety, and the volume the stomach will accept
What scintigraphy and breath-test studies established about emptying rate, and what they did not.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Turkey pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
From 0.25 to 2.4: reading a ladder as a series of ratios
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
New Zealand pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The label says four weeks. The clinic says whatever holds.
What the regulatory dossiers actually contain on dose selection is remarkably thin, and worth knowing before treating the ladder as settled science.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
The trade has decided the ceiling is arbitrary. The trials disagree.
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
The ceiling is a tolerability finding, not an efficacy one
Where the curve flattens, what flattens with it, and what does not.
Turkey pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Severity grading, and the gap between a grade and an experience
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.